439 related articles for article (PubMed ID: 19459152)
1. NPY revealed as a critical modulator of osteoblast function in vitro: new insights into the role of Y1 and Y2 receptors.
Teixeira L; Sousa DM; Nunes AF; Sousa MM; Herzog H; Lamghari M
J Cell Biochem; 2009 Aug; 107(5):908-16. PubMed ID: 19459152
[TBL] [Abstract][Full Text] [Related]
2. Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity.
Lee NJ; Doyle KL; Sainsbury A; Enriquez RF; Hort YJ; Riepler SJ; Baldock PA; Herzog H
J Bone Miner Res; 2010 Aug; 25(8):1736-47. PubMed ID: 20200977
[TBL] [Abstract][Full Text] [Related]
3. Hypothalamic control of bone formation: distinct actions of leptin and y2 receptor pathways.
Baldock PA; Sainsbury A; Allison S; Lin EJ; Couzens M; Boey D; Enriquez R; During M; Herzog H; Gardiner EM
J Bone Miner Res; 2005 Oct; 20(10):1851-7. PubMed ID: 16160743
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage functions in vitro: counter regulation through Y1 and Y2/5 receptors.
Dimitrijević M; Stanojević S; Vujić V; Beck-Sickinger A; von Hörsten S
Regul Pept; 2005 Jan; 124(1-3):163-72. PubMed ID: 15544855
[TBL] [Abstract][Full Text] [Related]
5. NPY regulation of bone remodelling.
Lee NJ; Herzog H
Neuropeptides; 2009 Dec; 43(6):457-63. PubMed ID: 19748118
[TBL] [Abstract][Full Text] [Related]
6. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system.
Pons J; Kitlinska J; Ji H; Lee EW; Zukowska Z
Can J Physiol Pharmacol; 2003 Feb; 81(2):177-85. PubMed ID: 12710532
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
8. Neuropeptide Y expression and function during osteoblast differentiation--insights from transthyretin knockout mice.
Nunes AF; Liz MA; Franquinho F; Teixeira L; Sousa V; Chenu C; Lamghari M; Sousa MM
FEBS J; 2010 Jan; 277(1):263-75. PubMed ID: 19954489
[TBL] [Abstract][Full Text] [Related]
9. Increased brain neuropeptide Y1 and Y2 receptor binding in NPY knock out mice does not result in increased receptor function.
Gehlert DR; Shaw JL
Peptides; 2007 Feb; 28(2):241-9. PubMed ID: 17208335
[TBL] [Abstract][Full Text] [Related]
10. Neuropeptide Y and the retinal pigment epithelium: receptor subtypes, signaling, and bioelectrical responses.
Ammar DA; Hughes BA; Thompson DA
Invest Ophthalmol Vis Sci; 1998 Sep; 39(10):1870-8. PubMed ID: 9727410
[TBL] [Abstract][Full Text] [Related]
11. Neuropeptide Y and osteoblast differentiation--the balance between the neuro-osteogenic network and local control.
Franquinho F; Liz MA; Nunes AF; Neto E; Lamghari M; Sousa MM
FEBS J; 2010 Sep; 277(18):3664-74. PubMed ID: 20681986
[TBL] [Abstract][Full Text] [Related]
12. NPY and Y receptors: lessons from transgenic and knockout models.
Lin S; Boey D; Herzog H
Neuropeptides; 2004 Aug; 38(4):189-200. PubMed ID: 15337371
[TBL] [Abstract][Full Text] [Related]
13. Induction of alkaline phosphatase activity by L-ascorbic acid in human osteoblastic cells: a potential role for CK2 and Ikaros.
Son E; Do H; Joo HM; Pyo S
Nutrition; 2007 Oct; 23(10):745-53. PubMed ID: 17664058
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2.
Nadiminty N; Lou W; Lee SO; Mehraein-Ghomi F; Kirk JS; Conroy JM; Zhang H; Gao AC
Clin Cancer Res; 2006 Mar; 12(5):1420-30. PubMed ID: 16533764
[TBL] [Abstract][Full Text] [Related]
15. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors.
Henry M; Ghibaudi L; Gao J; Hwa JJ
Obes Res; 2005 Jan; 13(1):36-47. PubMed ID: 15761161
[TBL] [Abstract][Full Text] [Related]
16. Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: evidence from receptor knockout mice.
Lin EJ; Young D; Baer K; Herzog H; During MJ
Epilepsia; 2006 Apr; 47(4):773-80. PubMed ID: 16650144
[TBL] [Abstract][Full Text] [Related]
17. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.
Seriwatanachai D; Thongchote K; Charoenphandhu N; Pandaranandaka J; Tudpor K; Teerapornpuntakit J; Suthiphongchai T; Krishnamra N
Bone; 2008 Mar; 42(3):535-46. PubMed ID: 18166509
[TBL] [Abstract][Full Text] [Related]
18. [Regulation of receptor activator of nuclear factor kappaB ligand and osteoprotegerin expression by prostaglandin E2 in osteoblastic-like cells].
Wang BL; Zheng F; Qiu MC
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1992-6. PubMed ID: 19062743
[TBL] [Abstract][Full Text] [Related]
19. Neuropeptide Y modulates steroid production of human adrenal H295R cells through Y1 receptors.
Kempná P; Körner M; Waser B; Hofer G; Nuoffer JM; Reubi JC; Flück CE
Mol Cell Endocrinol; 2010 Jan; 314(1):101-9. PubMed ID: 19699258
[TBL] [Abstract][Full Text] [Related]
20. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
